Robinhood Stock Nears $114 as Jobs Data Boosts Risk Appetite 
Circle Urges EU to Revise MiCA Stablecoin Rules 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Volvo Cars Drops Full-Year Outlook as China, US Sales Weaken 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
Malaysia Aviation Group to Buy Airbus SAE Unit 
Flydubai FZ1073 Co-Pilot Accused of Terror Attack 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
Amazon Eyes $8 Billion Nvidia Chip Spinoff to Fund AI Expansion 
Bank of America Sees EUR/USD at 1.15 by Year-End 
Add as a preferred source on Google
RESEARCH TRIANGLE PARK, N.C., May 09, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 16, 2017 at 5:00 p.m. Pacific Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst has several ongoing development programs: BCX7353 and other second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
